Abstract: Compounds of formula I their manufacture, pharmaceutical compositions containing them and their use as medicaments.

Abstract: The invention relates to a device (10) for determining the optical parameters of a user comprising: at least two image recording devices (14, 16), which are configured and arranged to respectively generate image data of at least sub-sections of the head of the user (30); a data processing unit comprising a user data determination device, which is configured to use the generated image data to determine user data relating to at least one sub-section of the head, or at least one sub-section of a system placed on the head that supports a pair of glasses (38) of the user (30) in a normal position of wear, the user data containing the three-dimensional location information of predetermined points in the head sub-section or the system sub-section and comprising a parameter determination unit, which is configured to determine at least some of the optical parameters of the user (30); a data output device, which outputs at least some of the determined optical parameters of the user (30).

Abstract: A series of spectacle lenses, where the position of use of the spectacle lenses in front of the eyes of the respective spectacle wearers, nominal variables at the intersection points of first lines of sight are essentially identical to the respective eye-sided or object-sided surfaces of the spectacle lenses. Each first line of sight is a predetermined, eye-sided line of sight, that intersects a pupil center point and an optical eye rotation point of the respective eye. All of the first lines of sight exhibit a predetermined, identical eye-sided visual angle.

Abstract: The invention relates to a spectacle lens device comprising at least one electrically adaptive area, wherein optical properties of the spectacle lens device can be controlled in an electric manner. The spectacle lens device is configured in such a manner that the optical properties of a predetermined or predeterminable control area can be controlled in an electrical manner which is essentially independent from the optical properties in a surrounding area. The invention also relates to the control area and to the surrounding area, respectively, about a partial area of the electrically adaptive area. The control area and the surrounding area do not a common area. The invention further relates to a pair of spectacles comprising a spectacle lens device, to the use of the inventive spectacle lens device and also to a method for operating an electrically adaptive area.

Abstract: A series of spectacle lenses, where the position of use of the spectacle lenses in front of the eyes of the respective spectacle wearers, nominal variables at the intersection points of first lines of sight are essentially identical to the respective eye-sided or object-sided surfaces of the spectacle lenses. Each first line of sight is a predetermined, eye-sided line of sight, that intersects a pupil center point and an optical eye rotation point of the respective eye. All of the first lines of sight exhibit a predetermined, identical eye-sided visual angle.

Abstract: The invention relates to a method of producing a single-strength spectacle lens while taking into account an individual spectacle wearer's data, the single-strength spectacle lens having a rotationally symmetrical base surface and a rotationally symmetrical aspherical or atoric prescription surface, comprising the following steps: Acquisition of an individual spectacle wearer's data; selection of a spectacle lens blank with a predetermined base surface from a group of spectacle lens blanks; and calculation and optimization of the prescription surface while taking into account at least a part of the individual spectacle wearer's data in addition to an adaptation of the dioptric effect by the prescription surface to the spectacle wearer's prescription. The invention also relates to a corresponding system for producing a single-strength spectacle lens and to an individual single-strength spectacle lens.

Abstract: Winding machine for winding a web of material divided into strips by longitudinal cuts, in particular a web of paper, plastic of metal foil, having two winding shafts that extend transversely across the machine width, which are positioned at one side of the machine in a pivotable turning device for moving from a winding position to a discharge position and back, whereby at the machine side opposite the turning device, a support device having a support element is arranged, which can be vertically moved by a drive, and which supports the end of a winding shaft on its way from the winding position to the discharge position.

Abstract: The invention relates to formulations containing the peptide p277 or variants thereof which are characterized by having increased stability during storage and transport.

Abstract: The present invention relates to the use of recombinant silicatein-? or silicatein-? isolated from natural sources as well as to silicatein-?-fusion proteins as well as silicatein-?-related enzymes for the synthesis, the degradation and for modification of silicon dioxide (condensation products of silicic acid, silicates), silicones and other silicon(IV)- or metal(IV)-compounds, and their technical uses.

Abstract: The present invention relates to compounds of formula (I) wherein R1, R2, R3, R4, R5, R6, m and X are as defined in the description and claims, and pharmaceutically acceptable salts thereof. The compounds are useful for the treatment and/or prophylaxis of diseases which are associated with the modulation of CB1 receptors.

Abstract: The present invention relates to compounds of formula (I) wherein R1, R2, R3, R4, R5, R6, m and X are as defined in the description and claims, and pharmaceutically acceptable salts thereof. The compounds are useful for the treatment and/or prophylaxis of diseases which are associated with the modulation of CB1 receptors.

Abstract: Compounds of formula I processes for their preparation, their use as pharmaceuticals and to pharmaceutical compositions comprising them.

Abstract: The present invention relates to compounds of formula (I): wherein —X—Y—, R1 to R11 and n are as defined in the description and claims, and pharmaceutically acceptable salts thereof. The compounds are useful for the treatment and/or prevention of diseases which are mediated by CETP inhibitors.

Abstract: Compounds of formula I wherein R1, R2, R4, R5, A, B, D and n are as defined, and pharmaceutically acceptable salts thereof, processes for their preparation, their use as pharmaceuticals and pharmaceutical compositions comprising them.

Abstract: Compounds of formula I their manufacture, pharmaceutical compositions containing them and their use as medicaments.

Abstract: Methods for an improved culturing of the fungus Penicillium chrysogenum, in particular strain KIP 3201, for an optimised production of the anti-tumour natural compound sorbicillactone A (2), and derivatives thereof in large amounts as well as optimised methods for the recovery and purification thereof from the fungal biomass and from the culture medium are described. Furthermore, the biological activity of sorbicillactone A (2), and studies regarding the genotoxicity of the compound are described.

Abstract: This invention provides novel methods of obtaining autologous monoclonal antibodies (AMABs) to self-antigens or homologs thereof. The method involves obtaining a genetically engineered host animal that does not biosynthesize at least one epitope of the antigen and utilizes the lack of self-tolerance of the host to the epitope to produce antibodies specific to the antigen. The invention also encompasses the AMABs produced by the methods. The invention further encompasses methods of isolating cells comprising the use of such AMABs that have specificity for a cell surface antigen.

Abstract: A method for the improvement of neuronal regeneration by prevention or inhibition of basal membrane formation induced by a lesion of neuronal tissue.

Abstract: Compounds of formula I as well as pharmaceutically acceptable salts and esters thereof, wherein R1, R2, R3 and A have the significance given in the specification are provided. The compounds can be used for the treatment or prevention of obesity.

Abstract: Compounds of formula I as well as pharmaceutically acceptable salts and esters thereof, wherein R1, R2, R3, A1 and A2 have the significance given in claim 1, can be used in the form of pharmaceutical preparations for the treatment or prevention of arthritis, cardiovascular diseases, diabetes, renal failure, eating disorders and obesity.